New Wave Endo-Surgical, Corp. – FDA 483, Oct 28, 2025

During an FDA inspection conducted from October 22-28, 2025, New Wave Endo-Surgical, Corp. was cited for significant deficiencies in its corrective and preventive action (CAPA) activities and documentation. The primary observation highlighted that the company failed to adequately implement its CAPA procedure, SOP-0020, leading to several procedural lapses.

Specifically, the firm closed CAPAs prematurely without fully verifying their effectiveness, such as CAPA-0007. Other instances included substantial delays in completing CAPA phases without proper justification, as seen with CAPA-0009. Furthermore, essential due dates for CAPA phases were frequently omitted, exemplified by CAPA-0010. A notable issue involved CAPA-0012, which was initiated to address a lack of sufficient manpower but was later disapproved despite the company having taken corrective action by hiring additional staff. These findings indicate a systematic failure to adhere to internal quality system requirements for managing nonconformances and preventing their recurrence.

The FDA noted that this inadequate documentation of CAPA activities is a repeat observation from a previous inspection. This signifies a persistent issue within the firm's quality management system. As per the regulatory framework, New Wave Endo-Surgical, Corp. is responsible for undertaking immediate corrective actions, conducting thorough internal self-audits, and ensuring comprehensive compliance with all quality system requirements to address these critical findings and prevent future recurrences.